对公大额存单
Search documents
南京医药股份有限公司关于公司及子公司继续使用部分暂时闲置募集资金进行现金管理的公告
Shang Hai Zheng Quan Bao· 2025-11-21 18:33
Core Viewpoint - The company plans to continue using up to RMB 500 million of temporarily idle raised funds for cash management, focusing on low-risk, high-liquidity investment products to enhance fund utilization efficiency and shareholder returns [2][18][49]. Fundraising Basic Situation - The company raised a total of RMB 1,081.49 million through the issuance of convertible bonds, with a net amount of RMB 1,069.04 million after deducting issuance costs [3]. - The funds have been deposited in a dedicated account for regulatory management to protect investor interests [3]. Fund Usage and Balance - As of June 30, 2025, the balance of the raised funds in the dedicated account was RMB 124.10 million [5]. - The company anticipates that some of the raised funds may remain idle for a certain period due to project progress [7]. Previous Cash Management Situation - In January 2025, the company approved the use of up to RMB 700 million of temporarily idle funds for cash management, investing in low-risk financial products [8]. - By October 2025, the company had utilized RMB 455 million for cash management, including structured deposits and large-denomination certificates of deposit [8]. Proposed Cash Management - The company aims to use up to RMB 500 million of temporarily idle funds for cash management to improve efficiency and reduce financial costs [9][10]. - The investment products will include high-safety, high-liquidity, and capital-protected financial products, with a maximum investment period of 12 months [11][12]. Approval Process - The board of directors held a temporary meeting on November 20-21, 2025, to approve the cash management proposal, which does not require shareholder meeting approval [18][49]. Impact on Daily Operations - The proposed cash management will not affect the normal operation of the company or the progress of fundraising projects, and it is expected to enhance overall performance and shareholder returns [17].
南京医药:关于公司及子公司使用部分暂时闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告
Zheng Quan Ri Bao· 2025-08-20 13:48
Core Points - Nanjing Pharmaceutical announced the use of 170 million yuan of temporarily idle raised funds to purchase a large corporate time deposit from Minsheng Bank, which matured on August 19, 2025 [2] - The company redeemed the principal of 170 million yuan and earned investment income of 573,800 yuan, which met expectations [2] - The company plans to continue using the same amount of 170 million yuan to purchase another large time deposit from Minsheng Bank with a term of 3 months and an annualized yield of 1.10% [2]